[1] It is also a adrenergic blocker with no partial agonist action and minimal membrane stabilizing activity.

This effect is thought to be caused by reducing the production of the liquid (which is called the aqueous humor) within the eye.

[4] It is a cardioselective beta blocker, targeting beta-1 adrenergic receptors found in the cardiac muscle.

[5][6] Ophthalmic betaxolol is an available treatment for primary open angle glaucoma (POAG) and optical hypertension.

[7] Furthermore, betaxolol is additionally able to protect retinal neurones following topical application from excitotoxicity or ischemia-reperfusion, providing a neuroprotective effect.